`platform-analysis`POST

VC-style competitive landscape for a biotech platform.

Analyzes a biotech platform and its competitive landscape from a VC diligence perspective. Given a query (and optional uploaded files such as decks, papers, or patents), it identifies the target company, maps platform claims to evidence, finds direct and adjacent competitors, builds a comparable company set, and surfaces key risks and diligence questions.

Endpoint

POST https://api.frontwind.ai/v1/agents/platform-analysis

Example

curl -X POST https://api.frontwind.ai/v1/agents/platform-analysis \
  -H "Authorization: Bearer fw_live_..." \
  -H "Content-Type: application/json" \
  -d '{ "query": "Platform competitive landscaping for CatenaBio's CysTyr/Catenase platform." }'

Request body

Field	Type	Required	Description
`query`	`string`	Yes	Free-form description of the platform to analyze. Example: 'Do platform competitive landscaping for CatenaBio\'s CysTyr/Catenase platform.'
`uploaded_files`	`array`	No	File IDs returned by POST /api/platform_analysis/files.
`use_cache`	`boolean`	default false

Response data

Field	Type	Description
`executive_summary`	`string`
`target_platform_overview`	`object`
`platform_claim_map`	`array`
`competitive_taxonomy`	`object`
`direct_competitors`	`array`
`adjacent_competitors`	`array`
`comparable_companies`	`array`
`differentiation_matrix`	`array`
`maturity_matrix`	`array`
`key_risks`	`array`
`diligence_questions`	`array`
`bottom_line`	`object`
`sources`	`array`
`warnings`	`array`
`generated_at`	`string`

Example response

{
  "ok": true,
  "agent": "platform-analysis",
  "data": {
    "executive_summary": "CatenaBio's Catenase platform uses engineered cysteine-tyrosine chemistry to enable site-specific ADC conjugation with homogeneous DAR. The platform competes directly with THIOMAB (Genentech/Roche) and maleimide-free rebridging approaches. Key differentiation is dual-residue flexibility, but clinical validation is absent.",
    "direct_competitors": [
      {
        "company": "Genentech/Roche",
        "platform": "THIOMAB site-specific conjugation",
        "status": "Established, multiple clinical programs",
        "why_relevant": "Earliest cysteine-based site-specific ADC platform; set industry benchmark",
        "differentiation_vs_target": "CatenaBio adds tyrosine residue flexibility; THIOMAB is cysteine-only",
        "threat_level": "High"
      }
    ],
    "bottom_line": {
      "is_real_platform": "Early-stage platform with credible chemistry but no clinical validation yet.",
      "strongest_differentiation": "Dual cysteine-tyrosine chemistry expands conjugation site repertoire.",
      "biggest_competitive_risk": "Genentech/Roche THIOMAB is entrenched; pharma may prefer incumbent.",
      "evidence_to_improve_conviction": "Preclinical PK/PD data head-to-head vs THIOMAB; partner deal."
    },
    "sources": [
      {
        "id": "S1",
        "title": "THIOMAB Technology",
        "url": "https://www.gene.com",
        "publisher": "Genentech",
        "date": "2023"
      }
    ],
    "warnings": [],
    "generated_at": "2026-05-23T00:00:00+00:00"
  },
  "elapsed_s": 42
}